The purpose of this study is to assess safety and tolerability of AZD1656 after single ascending oral doses in healthy male subjects

Inclusion Criteria:

• Provision of informed consent
• Clinically normal physical findings and laboratory values as judged by the investigator including negative test of Hepatitis B surface antigen, antibodies to HIV virus and antibodies to hepatitis C virus.

Exclusion Criteria:

• Clinically significant illness or clinically relevant trauma, as judged by the investigator, within 2 weeks before the first administration of the Investigational Product
• History of psychiatric or somatic disease/condition that may interfere with the objectives of the study, as judged by the investigator